NASDAQ:AIDX

20/20 Biolabs Q3 2026 Earnings Results & Report

20/20 Biolabs logo
$0.16 -0.02 (-13.01%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.16 +0.01 (+5.03%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

20/20 Biolabs reported Q3 2026 earnings on November 16, 2026. The company reported EPS of -$0.12, while revenue was $380.22 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes

20/20 Biolabs EPS Results

Actual EPS
-$0.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

20/20 Biolabs Revenue Results

Actual Revenue
$380.22 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

20/20 Biolabs Q3 2026 Earnings FAQ

20/20 Biolabs (NASDAQ:AIDX) reported earnings of -$0.12 per share for Q3 2026. The report was announced on Monday, November 16, 2026.

20/20 Biolabs reported revenue of $380.22 thousand for Q3 2026.

20/20 Biolabs Earnings Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More 20/20 Biolabs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 20/20 Biolabs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 20/20 Biolabs and other key companies, straight to your email.

About 20/20 Biolabs

20/20 Biolabs (NASDAQ:AIDX) is a clinical laboratory company that has provided diagnostic testing services, with a focus on infectious diseases. Its offerings have included COVID-19 testing, such as molecular and antibody-based tests, along with related laboratory services.

The company became known during the COVID-19 pandemic, when it supported demand for testing in the United States. Publicly available information about its broader operations and leadership is limited.

View 20/20 Biolabs Profile